Natriuretic Peptides, Heart, and Adipose Tissue: New Findings and Future Developments for Diabetes Research
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Natriuretic peptides (NPs) play a key role in cardiovascular homeostasis, counteracting the deleterious effects of volume and pressure overload and activating antibrotic and antihypertrophic pathways in the heart. N-terminal B-type NP (NT-proBNP) also is a promising biomarker of global cardiovascular risk in the general population, and there is increasing interest on its potential use in diabetic patients for screening of silent cardiovascular abnormalities, cardiovascular risk stratification, and guided intervention. Recently, both atrial NP (ANP) and B-type NP (BNP) have emerged as key mediators in the control of metabolic processes including the heart in the network of organs that regulate energy usage and metabolism. Epidemiological studies have shown that ANP and BNP are reduced in people with obesity, insulin resistance, and diabetes, and this deficiency may contribute to enhance their global cardiovascular risk. Moreover, ANP and BNP have receptors in the adipose tissue, enhance lipolysis and energy expenditure, and modulate adipokine release and food intake. Therefore, low ANP and BNP levels may be not only a consequence but also a cause of obesity, and recent prospective studies have shown that low levels of NT-proBNP and midregional proANP (MR-proANP) are a strong predictor of type 2 diabetes onset. Whether ANP and BNP supplementation may result in either cardiovascular or metabolic benefits in humans remains, however, to be established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Impact of Obesity on Plasma Natriuretic Peptide Levels
Wang, T. J., Larson, M. G., Levy, D., Benjamin, E. J., Leip, E. P., Wilson, P. W. F., & Vasan, R. S. (2004) · Circulation · doi:10.1161/01.cir.0000112582.16683.ea · Cited by 1,022
Bordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872 · cited 4×
“Indeed, rodents, which express NPR-C at high levels on adipocytes, have a blunted lipolytic response to NPs, and NPR-C deletion rescues their responsiveness (32).”
InfluentialMacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn153 · Cited by 694 · cited 3×
“In this regard, it is noteworthy that the PARADIGM-HF trial, testing efficacy and safety of the ARNi LCZ696 as compared with enalapril in patients with HFREF (34% with diabetes), has been stopped early based on evidence of compelling efficacy, and these promising incoming results may open the way to future trials in o…”
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514 · cited 3×
“If results are confirmed in humans, physicians may take advantage of this gut2heart link and use longacting GLP-1 receptor agonists to compensate for NP deficiency and gain indirect beneficial hemodynamic and metabolic effects mediated by ANP (45).”
Huelsmann, M., Neuhold, S., Resl, M., Strunk, G., Brath, H., Francesconi, C., Adlbrecht, C., Prager, R., Luger, A., Pacher, R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.069 · Cited by 385 · cited 1×
“125 pg/mL and no known cardiac disease randomized to a biomarker-guided “intensified” treatment (80).”
Boonman-de Winter, L. J. M., Rutten, F. H., Cramer, M. J. M., Landman, M. J., Liem, A. H., Rutten, G. E. H. M., & Hoes, A. W. (2012) · Diabetologia · doi:10.1007/s00125-012-2579-0 · Cited by 343 · cited 3×
“In this regard, it is noteworthy that the PARADIGM-HF trial, testing efficacy and safety of the ARNi LCZ696 as compared with enalapril in patients with HFREF (34% with diabetes), has been stopped early based on evidence of compelling efficacy, and these promising incoming results may open the way to future trials in o…”
Miyashita, K., Itoh, H., Tsujimoto, H., Tamura, N., Fukunaga, Y., Sone, M., Yamahara, K., Taura, D., Inuzuka, M., Sonoyama, T., et al. (2009) · Diabetes · doi:10.2337/db09-0393 · Cited by 288
G�de, P., Hildebrandt, P., Hess, G., Parving, H.-H., & Pedersen, O. (2005) · Diabetologia · doi:10.1007/s00125-004-1607-0 · Cited by 105 · cited 1×
“Recent studies also have demonstrated that NT-proBNP predicts cardiovascular events in T2D patients and has a greater predictive value than other well-established cardiac risk markers (2,75,76).”
Cited by
Zoccali, C., Vanholder, R., Massy, Z. A., Ortiz, A., Sarafidis, P., Dekker, F. W., Fliser, D., Fouque, D., Heine, G. H., Jager, K. J., et al. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.52 · Cited by 444
Molecular Physiology of Membrane Guanylyl Cyclase Receptors
Kuhn, M. (2016) · Physiological Reviews · doi:10.1152/physrev.00022.2015 · Cited by 356
Inter-tissue communication in cancer cachexia
Argilés, J. M., Stemmler, B., López-Soriano, F. J., & Busquets, S. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0123-0 · Cited by 305
Musclin is an activity-stimulated myokine that enhances physical endurance
Subbotina, E., Sierra, A., Zhu, Z., Gao, Z., Koganti, S. R. K., Reyes, S., Stepniak, E., Walsh, S. A., Acevedo, M. R., Perez-Terzic, C. M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514250112 · Cited by 198
Cardiovascular biomarkers in clinical studies of type 2 diabetes
Baldassarre, M. P. A., Andersen, A., Consoli, A., Knop, F. K., & Vilsbøll, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13247 · Cited by 22
“gene and both myocardial ischaemia and hypoxia are potent BNP inducers.(9) Indeed, since 2007, the assessment of NT-proBNP was included in guidelines for the use of biochemical markers in acute coronary syndrome.”
BackgroundInfluential
Metadata
- Authors
- Gruden, G., Landi, A., & Bruno, G.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-10-10
- Volume
- 37
- Issue
- 11
- Pages
- 2899-2908
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2017023895
- Cited by
- 130
- References
- 10
- FWCI
- 8.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Natriuretic Peptides, Heart, and Adipose Tissue: New Findings and Future Developments for Diabetes Research. https://app.cochat.ai/papers/10.2337/dc14-0669
- The paper
- Gruden, G., Landi, A., & Bruno, G. (2014). Natriuretic Peptides, Heart, and Adipose Tissue: New Findings and Future Developments for Diabetes Research. Diabetes Care. https://doi.org/10.2337/dc14-0669
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.